Search

Displaying results 1091 - 1100 of 10000 in total
  1. Drug

    Pirtobrutinib

    go.drugbank.com/drugs/DB17472
    ApprovedInvestigational

    [A256788] In January 2023, the use of pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy was approved under the FDA's Accelerated … in the presence of Cys481 mutations.

  2. Drug

    Larotrectinib

    go.drugbank.com/drugs/DB14723
    ApprovedInvestigational

    an important role in tumor cell growth and survival. … of cell growth in tumors that overexpress Trk.

  3. Drug

    Oxycodone

    go.drugbank.com/drugs/DB00497
    ApprovedIllicitInvestigational

    Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. … [A178696] It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics

    Products: ENDOCODIL IR
  4. Drug

    Metformin

    go.drugbank.com/drugs/DB00331
    ApprovedInvestigational

    Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes. … [A36559] Metformin was first approved in Canada in 1972,[A36552] and received subsequent FDA approval in the US in 1995.[L12207]

    Categories: Drugs Used in DiabetesProducts: METFORMIN ARISTO N 500MG, METFORMIN ARISTO N 850MG
  5. Drug

    Desipramine

    go.drugbank.com/drugs/DB01151
    Approved

    The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. … In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake.

    Synonyms: N-(3-methylaminopropyl)iminobibenzyl
  6. Drug

    Ublituximab

    go.drugbank.com/drugs/DB11850
    ApprovedInvestigational

    [A244210] Ublituximab is a chimeric anti-CD20 IgG1κ antibody produced in the rat YB2/0 cell line to target a unique epitope and enhance ADCC compared to other approved anti-CD20 antibodies such as [rituximab … CD20, an antigen expressed by various B and T cells, is an attractive therapeutic target in various cancers and autoimmune conditions.

  7. Target

    Antigen peptide transporter 1

    go.drugbank.com/bio_entities/BE0003109
    TransporterHumans

    In complex with TAP2 mediates unidirectional translocation of peptide antigens from cytosol to endoplasmic reticulum (ER) for loading onto MHC class I (MHCI) molecules (PubMed:25377891, PubMed:25656091

    Synonyms: Peptide transporter involved in antigen processing 1
  8. Drug

    Idelalisib

    go.drugbank.com/drugs/DB09054
    ApprovedInvestigational

    For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other … co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.

    Categories: Class Ia Phosphatidylinositol 3-Kinase, antagonists & inhibitors
  9. Drug

    Ancestim

    go.drugbank.com/drugs/DB09103
    ApprovedWithdrawn

    [T68] It was also approved by Health Canada in 1999 but it is currently under the status of canceled post-market.[L1087] … Ancestim was developed by Amgen and sold to Biovitrium in December 2008. It was submitted to the FDA under the status of recommendation for approval with a 10 to 1 votes.

  10. Drug

    Selinexor

    go.drugbank.com/drugs/DB11942
    ApprovedInvestigational

    [L7123] Selinexor was also granted accelerated approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have gone through at least 2 lines of … Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound.